-+ 0.00%
-+ 0.00%
-+ 0.00%

ADMA Biologics wins FDA approval expanding ASCENIV label to pediatric patients 2+

PUBT·05/04/2026 11:06:38
Listen to the news
ADMA Biologics wins FDA approval expanding ASCENIV label to pediatric patients 2+
  • FDA cleared ADMA Biologics supplemental BLA to expand ASCENIV label to pediatric primary humoral immunodeficiency patients aged 2 and older.
  • ASCENIV indication previously covered patients aged 12 and older.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.